Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Halted JV "should not have a material impact on our operations during the remainder of 2020.”
So there's that.
Perhaps Ekso's role with the DoD is not finished.
Maybe it's also a blessing in disguise to get out before China tensions heat up any further.
Profit margins have been on a nice path upwards regardless.
I'm not sure how I feel, but might view this as a buying opportunity depending what price does short term
CFIUS decides to halt China JV over national security concerns
https://ir.eksobionics.com/press-releases/detail/685/ekso-bionics-announces-cfius-determination-regarding-china
Yeah, lateral growth is important from the business end of things too.
I would also imagine that Ekso having more rehabilitation product offerings in general will have a positive effect for healthcare network deals; lowering costs through volume. Network provider deals appear to be a critical focus from management right now, so I'm happy to see this video showcasing the product.
There's also the perspective of how EksoUE will be affected by insurance policies looking further forward. Unpowered exoskeleton rehabilitation coverage may well be easier/simpler/cheaper for insurance providers to afford, at least compared to gait therapy devices. On the other hand, EksoNR has a lot of clinical data to go on....As a third option, there's also a possibility of exoskeleton rehabilitation getting covered more broadly down the middle too.
EksoUE seems to me like it has a much more clear entrance path to the home market compared point compared to battery powered gait therapy robotics (that would have the potential to leave someone stranded without power). It's almost sort of absurd to me, thinking back, that other companies tried to make gait therapy an at-home product so early on. I think they sort of got over-excited and Ekso's slow and steady pace going from inpatient to at-home will prove to be the winning strategy.
I'm long EKSO
A couple quick thoughts:
I would guess these horizontal rockinghorses on the way up shake a lot of people loose and dump em off at the curb for further gains. Perhaps intentional manipulation from smart/big money getting in? Yesterday's lower open on good news was some odd reverse-psychology making it feel like it's topped off, making holding somewhat daunting yesterday...I'm still long.
MNRNA seems to me to be a pretty good hedge against the broader market right now. I seem to be noticing a bit of a reverse correlation going on without diving into the math - perhaps someone else could comment here?
I'm always happy to hedge when it means surviving the storm.
Good luck everyone, but not everyone can win.
My take is to view Cramer much the way I'd imagine an Olympic wrestler views the WWE. Sure it's entertaining, but probably not often taken seriously by experts. I think Cramer himself probably knows this, but the show must go on- right?
My first MRNA buy was executed at ~29.53
I'm long MRNA
I agree, much more run to go. Holding strong, holding long
https://investors.modernatx.com/financial-information/sec-filings
All of today's Form 4's are (A)cquisitions
Traders moving out, smart money moving in - just my read on things
Check out the CEO's TEDx talk from 6 years ago. only 25,655 views.
good minimalism
I think more people reacted to the nasdaq contributor article asking whether it came too far to fast and raising doubts more than this news. Just my guess.
That's a little ridiculous in my opinion.
The funding is already secured and the NIH is extremely prestigious too, involved in more than just initial development. NIH is involved in manufacturing and testing too. So his transition could even accelerate vaccine development, right? Seems like he's moving down the pipeline along with the vaccine to me. Not exactly a disgraced resignation that bears would hope for.
I'm long MRNA
https://www.niaid.nih.gov/research/vaccine-development-services
"The person can become the bioreactor" - Dr. Amy Jenkins, DARPA Program Manager - Biological Technologies Office (BTO)
That's one of the things I heard that made me invest in MRNA. Well, not specifically this ear-catching statement, but the whole podcast.
Anyhow, I'd point out these two source materials as part of my due dilligence. One is a DARPA podcast mentioning Moderna and the other is a MRNA press release mentioning DARPA. I think it's important perspective to see it from both sides, but be advised it's also easy to fall into circular reasoning if not careful.
https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-positive-phase-1-results-first-systemic
Steps are still going up: https://eksobionics.com/eksohealth/
I stand corrected
So glad I bought in 4/14 and 4/15!!!!
I had listened to this Voices From Darpa podcast about pandemic prevention a few times (the PM mentions moderna), and then I put the stock on my watchlist. Saw the embers starting to glow and pulled the trigger on a long buy. Couldn't be happier
Voices From Darpa 24:
Possible short squeeze might be on horizon if gains keep up at this rate
I'm long EKSO
THIS GONNA BE EKSO'S YEAR
Market timing seems to be doing us a favor somehow
So much dread over the R-S and now current price is higher than when it happened.
Good news could be a major catalyst right now
I'm long EKSO
Ekso, the contrarian miracle stock coming in hot today
or...something like that
I'm long EKSO
https://ir.eksobionics.com/press-releases/detail/682/ekso-bionics-provides-covid-19-business-update-and-reports
Largely expected, but not great news
...What % of staff did they furlough? AT least the CARES Act will minimize the impact hopefully
I'm long EKSO
Ekso Bionics moves into mining: Safety MITS (Mining Industrial Trade Supplies) is selling their products.
See the EksoVest and ZeroG prominently featured on their website
https://safetymits.com
Saftey MITS also sells to the aerospace, construction, engineering, service, health, mining and earth-moving industries.
Cash on hand is going up and operating expenses are going down.
Cash on hand at December 31, 2019 was $10.9 million, compared to $7.7 million at December 31, 2018. For the full year ended December 31, 2019, the Company used $15.8 million of cash in operations, compared to $22.2 million for the same period in 2018.
Total operating expenses decreased by 29% to $4.7 million in the fourth quarter of 2019, compared to $6.6 million in the same period of 2018.
are you short EKSO, Princes?
I'm long EKSO
This is a stock-specific board so I try not to talk about my other investments, which include many blue chip and/or high dividend stocks in various sectors. There are other high-tech interests I have, but much of what I'm interested in falls under the jurisdiction of relatively massive companies. There is a rule of thumb that generally penny stocks should be a small fraction of a portfolio and I agree- without giving advice of course.
In general, I tend to think penny stocks are less-than-favorable investments. At under $5 -EKSO is very much a penny stock. Being on the NASDAQ compared to OTC helps and winning multiple DARPA contracts helps ease my mind a little too. Pilot program with Ford and Boeing help more. The Admiral who led the raid on Osama Bin Laden said the collaboration involving Ekso "is the future of how we do business." Then there is the paralyzed person who was able to move after using Ekso+FES. Also, Steph Curry taking a photo with an EksoGT gave me a little bit more assurance. I guess that I've seen enough and will take my chances with holding onto this one.
P.S.
Never say never
Yeah, better to get it over with than to leave it hanging - at least in my opinion. Today was a hemorrhage admittedly.
At the end of the day, I can live with the losses knowing I'm supporting a company that's doing good in the world. I still think there is a path forward.
I'm long EKSO
Clinical trial update: Three clinical trials using Ekso are enrolling/recruiting
https://clinicaltrials.gov/ct2/show/NCT04250688?term=Ekso+Bionics&draw=2&rank=10
1) Robotic Exoskeleton With Functional Electrical Stimulation in Acute Spinal Cord Injury
Sponsor:
Shirley Ryan AbilityLab
Collaborator:
U.S. Department of Education
Information provided by (Responsible Party):
Arun Jayaraman, PT, PhD, Shirley Ryan AbilityLab
2) Robotic Exoskeleton Assisted Gait Post Stroke (RE-Assist)
Sponsor:
Kessler Foundation
Information provided by (Responsible Party):
Karen J. Nolan, PhD, Kessler Foundation
3) Exoskeleton-assisted Training to Accelerate Walking Recovery Early After Stroke: the TARGET Phase II Study (TARGET)
Sponsor:
Universiteit Antwerpen
Collaborator:
University Hospital, Antwerp
Information provided by (Responsible Party):
Jonas Schröder, Universiteit Antwerpen
----------
I think it's worth pointing out the definition of collaborator in this context: Organizations providing support in funding, design, implementation, data analysis or reporting.
Ekso is not alone!
I'm long EKSO
I think that's the difference between a pilot program and clinical trial. The pilot is funded by Kindred, but I don't think it's necessarily a clinical trial. EksoPulse data seems like it'll still be collected, so there is at least some data to be analyzed in terms of research. Perhaps I'm misunderstanding something?
"Is it the responsibility of the investor to memorize what each company in the field means by its marketing material?"
Yes, it is the responsibility of the investor to do their own due diligence. How much investors are able to look past the balance sheet and into the science/terminology of exoskeleton usage is a good question.
To me, what you speak of is exactly why the Kindred Healthcare pilot of EksoNR in Ltac hospitals is such an important milestone for Ekso Bionics. I think this specific example showcases why Ekso is not alone. Instead of Ekso having to fund their own research, others are pushing Ekso into new domains via pilot while Ekso gets to make money while doing it. This is radical for Ekso and to me it's a really, really good sign.
In the industrial vest space: weight, cost, lift assistance, warranty, availability are some basic metrics that come to mind. It would be nice to see more ergonomics: for instance some sort of standardized 'average external forces' for normal use. It'll be interesting to see post-pilot acquisitions and if they create a pattern.
I'm long EKSO
Both are largely devalued, but which one has a better chance to recover remains a question.
Actively shorting? Or just talk?
Any updates on shareholder meeting?
You both seem panicky and neither of you bring new info to the table, only basing your opinions on past performance. That's not a good strategy and it's not really helpful to the people focused on facts and information - spending time doing real due dilligence.
Let's try to keep the emotional baggage to a minimum please
The China JV might be slowed down temporarily, but the entire market is slowed down too - so it's relative. Important to note that last Q still saw improvements on profit margins.
Either do some original research or at least give specifics to why you are worried about where the company now stands. Broadly complaining about China isn't going to cut it
To the bulls,
Hopefully we continue to see network healthcare providers buy multiple units, especially in the long term acute care space. This will likely silence the bears
I'm long EKSO
Picked up some more shares today at ~.29
Yes, only winners can win and only losers can lose, LOSER!
What a small brained, pathetic idea
A contrarian believes that certain crowd behavior among investors can lead to exploitable mispricings in securities markets.
Yes, this company's runway to success has been long and painful for shareholders - as many startups are. This has very little bearing on whether or not the company will be able to succeed going forward. I believe Ekso is still far outstripping their competitors and the exoskeleton field is expected to grow enormously.
Stocks in general are risky, and penny stocks even more so.
If you don't have a strong stomach (or brain), investing in securities probably isn't for you
The New EksoUE From Ekso Bionics: https://www.ectron.co.uk/eksoue
EksoUE is a wearable upper-extremity eksoskeleton designed to assist a patient's affected shoulder and arm during rehabilitation. developed in partnership with Johns Hopkins Medicine and clinically trialled by industry-leading rehab centre across the US, EksoUE was engineered for patients suffering from upper-extremity paralysis or weakness.
With EksoUE, patients can achieve rehab sessions with a higher dosage, more intensive therapy, and a wider active range of motion. Additionally, it can be used in conjunction with task-specific activities, gaming solutions, and various activities of daily living (ADL's) tasks. EksoUE's comfortable and simple design provides Physiotherapists and Occupational Therapists with a new tool to reduce the gravity load on one or both arms for patients while sitting, standing or ambulating
Wearable & Mobile:
EksoUE can be used while sitting, standing and moving around which is particularly useful in ADL scenarios. The EksoUE does not rely on any electronics or batteries needing charging.
Better Therapy:
EksoUE allows the patient to exercise a wider range of motion than without support by compensating for gravity. Supports the patients arm with minimal interference, allowing for a more natural motion than other devices or traditional therapy. Reduces fatigue, allowing patients to tolerate a high therapy dosage for longer by supporting the patients arm.
Easy to Use:
Easily reconfigured for a range of force levels and sizes, allowing use on a wide range of patients and adaptive to patient goals. Provides access to shoulder joint and scapula to help therapists facilitate movement. Simple to set up and use, with a self guided training module.
For more information about this product or to book a demonstration, please call Ectron on 0117 941 3979 or email: enquiries@ectron.co.uk.
Alternatively please complete the contact form below.
Please note: Available for delivery at the end of Q1 2020
https://www.ectron.co.uk/eksoue
Looks good %gain wise, but net loss for the Q never feels good.
This comment seems to get more true every day regarding the outlook. Positive news seemed overwhelmed by reverse-split prospects. I think it'd be need to be pretty big news to overcome.
How much does this cost by the way? Not listed? Any pilot programs? is it for sale yet?
Let's start with the simple questions.
Ekso Vest seems to be far ahead of the competition if not only for being actually available for purchase on their website. The rest of the details are largely secondary in terms of competing in the marketplace.
"Previously exclusively used in research, Hasomed’s Rehastim2 FES integration with Ekso is now available for routine clinical use in registered CE marked countries."
No other rehabilitation exoskeletons are available with FES that I've seen so far - please post a correction if I'm wrong here.
The more I think about this, the more I think it's a game changer.
https://eksobionics.com/eksohealth/hasomed-partnership/
They don't say how much it lifts, not in specs
I do see 4.0 kg weight, but they don't say how much it lifts and the ratio is what I'm most focused on the most
Fiat Chrysler owned Italian version of Ekso Vest: